Clinical trial · Interventional
68Ga-PMD22 PET/CT Examination Targeting CLDN18.2
CLDN18.2 Targeted 68Ga-PMD22 PET Imaging in Patients With Gastrointestinal Tumours
NCT05937919CI-TRIAL-00067873unknownEarly Phase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To investigate the ability of the CLDN18.2-targeted 68Ga-PMD22 tracer to detect CLDN18.2 expression in patients with gastric and colorectal cancer and other gastrointestinal tumours.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastrointestinal Cancer | Malignant Digestive System Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Intravenous injection of 68Ga-PMD22 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- 68Ga-PMD22 PET/CT dynamic scan
- description
- 68Ga-PMD22 PET/CT scan Dosimetry study about 6 patients were injected with 2-4 (MBq) per kilogram body weight of 68Ga-PMD22 PET/CT in one dose intravenously and underwent wholebody scan at 5min#15min#30min#60min#90min#120min#180min, then analysis of dosimetric distribution of radiopharmaceuticals in human body by HERMES software.
- interventionNames
- Drug: Intravenous injection of 68Ga-PMD22
- type
- EXPERIMENTAL
- label
- 68Ga-PMD22 PET/CT scan at one time
- description
- After the dynamic scan completed, choose an optimal imaging examination time for PET examination of other patients.
- interventionNames
- Drug: Intravenous injection of 68Ga-PMD22
Primary outcomes (2)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * In the near future (within 2 months), patients who plan to undergo puncture biopsy or undergo tumor surgical treatment or are clinically highly suspected of cancer (including primary and tumor recurrence and metastasis) * Able to understand and voluntarily sign informed consent forms, with good compliance Exclusion Criteria: * Severe abnormalities in liver and kidney function * Suffering from claustrophobia or other mental illnesses * Pregnant and lactating women
References
Publications (1)
- DERIVEDWang R, Bai Z, Zhong W, Li C, Wang J, Xiang J, Du J, Jia B, Zhu Z. Synthesis, preclinical evaluation and pilot clinical translation of [68Ga]Ga-PMD22, a novel nanobody PET probe targeting CLDN18.2 of gastrointestinal cancer. Eur J Nucl Med Mol Imaging. 2024 Oct;51(12):3731-3743. doi: 10.1007/s00259-024-06808-5. Epub 2024 Jun 27. PMID 38926162